Compare · FEMY vs MDLN
FEMY vs MDLN
Side-by-side comparison of Femasys Inc. (FEMY) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FEMY and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.86B, about 1963.1x FEMY ($23.9M).
- FEMY has been more active in the news (19 items in the past 4 weeks vs 12 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 3 for FEMY).
- Company
- Femasys Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- $23.9M
- $46.86B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2025
- News (4w)
- 19
- 12
- Recent ratings
- 3
- 25
Femasys Inc.
Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Latest FEMY
- Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
- SEC Form D filed by Femasys Inc.
- Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
- SEC Form 10-Q filed by Femasys Inc.
- Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
- Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
- SEC Form 4 filed by Director Eichenbaum Kenneth D.
- SEC Form 4 filed by Director Uzialko Edward R
- SEC Form 4 filed by Director Milnes Alistair
- SEC Form 4 filed by Director Larsen Charles
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.